Finland· FI-REL-REL40834
Betaferon
A interferon beta-1b product containing interferon beta 1b, registered in Finland by Orifarm Oy. The same ATC class is registered in 14 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Interferon beta-1b is registered in 14 of 19 countries.
Countries holding a registration under ATC L03AB08 (interferon beta-1b), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Interferon beta-1b · ATC L03AB08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
The record
At a glance
Fimea (Finland)- Active substance
- Interferon beta 1b
- Manufacturer
- Orifarm Oy
- Country
- Finland (FI)
- ATC code
- L03AB08
- ATC class
- Interferon beta-1b
- Defined daily dose
- 4 MIO, E
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
347 interactions on record for interferon beta-1b.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Interferon beta-1b · interactions on record
347 records
- 15 severe
- 332 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- ZidovudineJ05AF01severe
- ClotrimazoleA01AB18moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Interferon beta-1b in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBETAFERONBayer AG, Leverkusen
- SpainBETAFERON 250 MICROGRAMOS/ML POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEBayer Ag
- United KingdomBetaferon 300microgram powder and solvent for solution for injection vialsOriginalis B.V.
- BelgiumBetaferon 0.25 mg/mlBayer
- FranceBETAFERON 250 microgrammes/ml, poudre et solvant pour solution injectableBAYER AG (ALLEMAGNE)
- PolandBetaferonBayer AG
- NetherlandsBetaferon, poeder en oplosmiddel voor oplossing voor injectieBayer AG
- NorwayBetaferonBayer AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Betaferon
- Liechtenstein · Betaferon
- Norway · Betaferon
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d967bedd-82b7-4f5a-a33c-25a1578c74a6 GET /v1/drugs/d967bedd-82b7-4f5a-a33c-25a1578c74a6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "4",
"form": "injektiokuiva-aine ja liuotin, liuosta varten",
"route": "Ihon alle",
"ddd_unit": "MU",
"strength": "250 mikrog/ml",
"atc_label": "interferoni beeta-1b",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/95/003/005",
"fimea_rel_id": "REL40834",
"authorised_at": "2011-10-20"
}See everything about interferon beta-1b.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.